This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 14.61% and 0.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $12.20, indicating a +0.66% shift from the previous trading day.
BrightSpring Health Services, Inc. (BTSG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.78% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 19.93% and 5.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Laps the Stock Market: Here's Why
by Zacks Equity Research
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
by Zacks Equity Research
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?
by Zacks Equity Research
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Organon (OGN) Stock Moves -1.83%: What You Should Know
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $14.45, signifying a -1.83% move from its prior day's close.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Organon (OGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $14.51, signifying a -0.34% move from its prior day's close.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session.
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $15.39, denoting a -1.35% change from the preceding trading day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 4.65% and 1.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?